SG Americas Securities’s Cardiff Oncology CRDF Stock Holding History

SG Americas Securities’s Portfolio CRDF Stock Details CRDF Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	–	Sell	-10,057	Closed	-$16K	–	3402
2026 Q1	$16K	Sell	10,057 -5,741	-36%	-$11.8K	﹤0.01%	3114
2025 Q4	$44K	Buy	+15,798	New	+$36.7K	﹤0.01%	3378
2025 Q2	–	Sell	-23,029	Closed	-$72K	–	3055
2025 Q1	$72K	Buy	23,029 +5,195	+29%	+$20.5K	﹤0.01%	3148
2024 Q4	$77K	Sell	17,834 -6,103	-25%	-$19.1K	﹤0.01%	2806
2024 Q3	$64K	Buy	+23,937	New	+$56.5K	﹤0.01%	3192
2022 Q2	–	Sell	-38,693	Closed	-$96K	–	3441
2022 Q1	$96K	Buy	38,693 +2,401	+7%	+$8.49K	﹤0.01%	2776
2021 Q4	$218K	Sell	36,292 -15,966	-31%	-$95.2K	﹤0.01%	2628
2021 Q3	$348K	Buy	+52,258	New	+$328K	﹤0.01%	2804
2017 Q2	–	Sell	-471	Closed	-$39K	–	3218
2017 Q1	$39K	Buy	471 +324	+220%	+$44K	﹤0.01%	3138
2016 Q4	$22K	Sell	147 -26	-15%	-$6.07K	﹤0.01%	2984
2016 Q3	$56K	Buy	+173	New	+$63.1K	﹤0.01%	3166

Other funds holding CRDF

LCM

Laurion Capital Management New York $3.9B AUM 75.03% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Pfizer New York $170M AUM 191.09% 1-Year Est. Return

Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

William Blair & Company Chicago, Illinois $38.4B AUM 25.71% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return

Jane Street New York $1.21T AUM 78.12% 1-Year Est. Return

Vanguard Fiduciary Trust Malvern, Pennsylvania $454B AUM

SG Americas Securities's CRDF Position: Q2 2026 in Review

SG Americas Securities sold out of Cardiff Oncology (CRDF) in Q2 2026, closing a stake of 10,057 shares — an estimated $16K sold.

SG Americas Securities first reported a position in CRDF in Q3 2016 and held it in 11 quarters. The position peaked at $348K in Q3 2021. 105 funds tracked by Wall St. Rank hold CRDF as of Q2 2026.

SG Americas Securities reported no remaining Cardiff Oncology position as of Q2 2026 after selling out during the quarter.
SG Americas Securities sold 10,057 Cardiff Oncology shares in Q2 2026, an estimated $16K.
SG Americas Securities first reported a position in Cardiff Oncology in Q3 2016 and held it in 11 quarters.
SG Americas Securities's Cardiff Oncology position peaked at $348K in Q3 2021.
105 funds tracked by Wall St. Rank held Cardiff Oncology as of Q2 2026.

Based on SG Americas Securities's 13F filing for Q2 2026, filed 7 Aug 2026.